ACLY and cancer: Similarly, in another study, aPL antibodies were not significantly associated with thrombotic complications in cancer patients, and 72.2% of the thrombotic solid cancer patients were positive for IgM aCL compared to 57.1% in non-thrombotic solid cancer cases in that study [31].